They joined us !
Creation : 13/10/2023
Employees : 1
Address : Lyon
Activity (biotech/medtech/healthtech) : medtech
Who ?
Smartery is developing the first endoprosthesis for a fully endovascular treatment of aortic arch dissections. This Class III medical device aims to provide a curative solution for the 200,000 patients worldwide who, each year, lack access to surgical treatment.
After four years of R&D funded by SATT Pulsalys, this device—patented as a joint property of HCL, CNRS, INSERM, UCBL1, and UJM—has successfully completed its initial animal trials and aims for its first human implantation in 2027.
Pourquoi avoir intégré Lyonbiopôle ?
“Joining Lyonbiopole offers the opportunity for Smartery to join the rich ecosystem of the lyonese Health innovation ! Born and supported since its beginnings by the Lyon institutions HCL and SATT Pulsalys, Smartery continues its local development via Lyonbiopôle. We want to benefit from this community to exchange, meet partners and grow through the support provided by the teams and the network of this unique innovation hub!”
Benoit Cosset, CEO